Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognizing its innovative approach to addressing cancer drug resistance. The award highlights the company's strategy centered on resistance-modulating treatments, including its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies. Kairos Pharma is advancing combination approaches aimed at improving the durability of response across multiple cancer indications.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The Pinnacle Award underscores the importance of Kairos Pharma's work in a field where drug resistance remains a major challenge in oncology. Many patients initially respond to therapy but eventually relapse due to resistance mechanisms. By targeting CD105, ENV-105 may offer a way to prolong the effectiveness of existing treatments, potentially improving outcomes for patients with hard-to-treat cancers. The recognition also brings attention to the broader need for innovation in overcoming resistance, which could spur further research and investment in this area.
For more information about Kairos Pharma and its pipeline, visit the company's newsroom at https://ibn.fm/KAPA. The full press release announcing the award can be accessed at https://ibn.fm/ghPJC.
